Darunavir CAS 206361-99-1 Darunavir & its intermediates

Model: C27H37N3O7S
Place of Origin: Zhejiang,China (Mainland)
Brand Name: MOSINTER
CAS No.: 206361-99-1
Brand: MOSINTER
Molecular Formul: C27H37N3O7S
CAS NO.: 206361-99-1
Molecular Weight: 547.6636
Mp: 74-76°C
Density: 1.34g/cm3
Refractive index: 1.62

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:6 Kilogram/Year
Min. Order:1 GramPacking:According to the...
Means of Transport:Ocean, Air, LandDelivery Date:within 7 days

Darunavir CAS: 206361-99-1


Molecular Formula:

C27H37N3O7S

Molecular Weight:

547.6636

CAS Registry Number:

206361-99-1

Density

1.34g/cm3

Refractive index

1.62

Mp

74-76°C



Molecular Formula


Darunavir (formerly known as TMC114) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents.


Darunavir is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Early PIs often have severe side effects and drug toxicities, require a high therapeutic dose, are costly to manufacture, and show a disturbing susceptibility to drug resistant mutations. Such mutations can develop in as little as a year of use, and effectively render the medicine useless.


Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs.[3][4]


Darunavir received much attention at the time of its release, as it represents an important treatment option for patients with drug-resistant HIV. Patient advocacy groups pressured developer Tibotec not to follow the previous trend of releasing new medicine at prices higher than existing medicine in the same class. Darunavir was priced to match other common PIs already in use, such as the fixed-dose combination drug lopinavir/ritonavir.


Medical uses

Darunavir is an OARAC (DHHS) recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents. It showed comparable efficacy to lopinavir/ritonavir at 96 weeks with a once-daily dosing in treatment-naïve patients.


Side effects

This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed.

As with other antiretrovirals, darunavir does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

In studies, darunavir was generally well tolerated. Mild to moderate rash was seen in 7% of patients. Some patients developed severe rash. In clinical studies, 0.3% of patients discontinued due to rash. The most common moderate to severe side effects associated with darunavir include diarrhea (2.3%), headache (3.8%), abdominal pain (2.3%), constipation (2.3%), and vomiting (1.5%). Four percent of patients discontinued treatment due to adverse events. People who are allergic to darunavir or any of its ingredients, or ritonavir (Norvir) should not take darunavir.

Relevant drug-drug interactions with other medications commonly used in HIV patient populations were few, such as other antiretroviral medications, proton pump inhibitors, and H2 receptor antagonists. St. John's wort may reduce its effectiveness by interaction with CYP3A. Patients should talk to their healthcare providers about all the medicines they are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Before taking darunavir, patients should tell their healthcare providers if they have any medical conditions, including diabetes, liver problems, hemophilia, or allergy to sulfa medicines, and should tell their doctors if they are pregnant or planning to become pregnant, or are nursing. Darunavir should be used with caution in patients with hepatic impairment.

High blood sugar, diabetes or worsening of diabetes, muscle pain, tenderness or weakness, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines like darunavir. Changes in body fat have been seen in some patients taking anti-HIV medicines, including loss of fat from legs, arms and face, increased fat in the abdomen and other internal organs, breast enlargement, and fatty lumps on the back of the neck. The cause and long-term health effects of these conditions are not known at this time.

Clinial laboratory safety observed in the darunavir group was comparable to the control group.


Mechanism of action

Darunavir is a nonpeptidic inhibitor of PR that lodges itself in the active site of PR through a number of hydrogen bonds. It was developed to increase interactions with HIV-1 protease and to be more resistant against HIV-1 protease mutations. With a Kd value of 4.5 x 10−12 M, darunavir has a much stronger interaction with PR and its dissociation constant is 1/100 to 1/1000 of other protease inhibitors. This strong interaction comes from increased hydrogen bonds between darunavir and the backbone of the PR active site . Darunavir's structure allows it to create more hydrogen bonds with the PR active site than most PIs that have been developed and approved by the FDA. Furthermore, the backbone of HIV-1 protease maintains its spatial conformation in the presence of mutations. Because darunavir interacts with this stable portion of the protease, the PR-PI interaction is less likely to be disrupted by a mutation

Category: Antibiotic Drugs API

Related Category: Veterinary Medicine API  Diagnostic Agents API  Vitamin Preparation API  Psychotropic Drugs API  Endocrine Drugs API 


«
Offline Showroom in USA
QR Code